(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane Cas:119302-24-8

We are (2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane CAS:119302-24-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane

Synonyms:
(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane
RocuroniuM BroMide InterMediate VIII

 
Molecular Formula: C29H48N2O4
Molecular weight: 488.70200
 
Physical Properties:
Density: 1.17
Boiling point: 574.1ºC at 760 mmHg
Flash point: 301ºC
Refractive index: 1.573
Vapor Pressure: 1.44E-15mmHg at 25°C

 
Specification:
Items of Analysis Standard of Analysis Test Results
Appearance Pale yellow to almost white solid Conform
Solubility Soluble in CHCl3 Conform
Specific optical rotation +52.0~57.0°(c 1.23, CHCl3) +53.9°
Loss on Drying Not more than 0.7% 0.25%
Assay by HPLC Not less than 98 % Conform
LK-7 Not more than 0.2% Conform
Other largest single impurity Not more than 0.1% Conform
Conclusion Conforms to Factory Standard
 

 
Application:
Rocuronium Bromide Intermediate.
 
Package and Storage:
/



Market News:Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.” N-[3-(5-methyl-1(3)H-benzoimidazol-2-yl)-propyl]-aniline manufacturer.So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]pentanedioic acid supplier.The US-based study is evaluating the effect of ensifentrine on key outcomes in patients hospitalised with COVID-19, including facilitation of recovery from the viral infection, clinical status improvement and reduction in supplemental oxygen use and progression to mechanical ventilation. 6-(4-hydroxy-13,24,33,44,53,63-hexaoxin-2-yl)-1-(1,3,4,5,6-pentahydroxy-14,24,34,44,54,64-hexaoxin-2-yl)-24-hexaoxidan-2-one producer.

Related Products
Product Name
4-Methylphthalic Acid View Details
7-Chloro-2-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]amino]-2-heptenoic acid View Details
DIBENZYL OXALATE Cas:7579-36-4 View Details
1-Amino-1-(hydroxymethyl)cyclopropane Hydrochloride Cas:115652-52-3 manufacturer 2-Methoxy-6-methylpyridine manufacturer 9-bromo-11,11-dimethylbenzo[a]fluorene manufacturer 3,4-Difluorobromobenzene Cas:348-61-8 manufacturer methyl 3-bromo-2-fluorobenzoate manufacturer